Health experts are sounding the alarm over a disturbing trend where drug users swap blood to score a secondhand high. Called ...

In what may be one of the most important HIV research breakthroughs in years, scientists have discovered a strikingly ...

Lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, has shown 100% efficacy in preventing HIV in women at a high risk for infection, according to an interim analysis of the phase 3 PURPOSE ...

The spread of human immunodeficiency virus 1 (HIV-1) infections increased despite restrictions on the border between Mexico and the United States during the COVID-19 pandemic, according to a ...

Due to antiretroviral therapy, individuals with HIV are ageing and their risk for age-related comorbidities is increasing.

Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...

LONDON, GREATER LONDON, UNITED KINGDOM, October 13, 2025 /EINPresswire.com/ -- How Much Is The Human Immunodeficiency Viruses (HIV) Clinical Trials Market Worth? Over the past several years, the ...

Merck Sharp & Dohme LLC (MSD) has synthesized new N-oxide derivative targeted activator of cell kill (TACK) compounds acting as Gag polyprotein (HIV-1)/protein Pol dimerization inducers reported to be ...

A Prescription Drug User Fee Act target date of April 28, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir ...